 | Up a level |
Pagani, O; Klingbiel, D; Ruhstaller, T; Nolè, F; Eppenberger, S; Oehlschlegel, C; Bernhard, Jürg; Brauchli, P; Hess, D; Mamot, C; Munzone, E; Pestalozzi, B; Rabaglio, Manuela; Aebi, S; Ribi, K; Rochlitz, C; Rothgiesser, K; Thürlimann, B; von Moos, R; Zaman, K; ... (2017). Do all patients with advanced HER2 positive breast cancer need upfront-chemo when receiving trastuzumab? Randomized phase III trial SAKK 22/99. Annals of oncology, 28(2), pp. 305-312. Oxford University Press 10.1093/annonc/mdw622
Rochlitz, C; Ruhstaller, T; Lerch, S; Spirig, C; Huober, J; Suter, T; Bühlmann, M; Fehr, M; Schönenberger, A; von Moos, R; Winterhalder, R; Rauch, D; Müller, A; Mannhart-Harms, M; Herrmann, R; Cliffe, B; Mayer, M; Zaman, K; Swiss Group for Clinical Cancer Research, (SAKK) (2011). Combination of bevacizumab and 2-weekly pegylated liposomal doxorubicin as first-line therapy for locally recurrent or metastatic breast cancer. A multicenter, single-arm phase II trial (SAKK 24/06). Annals of oncology, 22(1), pp. 80-5. Oxford: Oxford University Press 10.1093/annonc/mdq319
Hess, D; Koberle, D; Thurlimann, B; Pagani, O; Schonenberger, A; Mattmann, S; Rochlitz, C; Rauch, D; Schuller, J C; Ballabeni, P; Ribi, K (2007). Capecitabine and vinorelbine as first-line treatment in elderly patients (> or =65 years) with metastatic breast cancer. A phase II trial (SAKK 25/99). Onkologie, 73(3-4), pp. 228-37. Basel: Karger 10.1159/000180915
